

# AeroEclipse® XL BAN® Nebuliser<sup>†</sup> and Ombra® Table Top Compressor

## Complete delivery systems for true *on-demand* therapy


- ✓ **Dose assurance**<sup>1</sup> - breath actuation only produces aerosol on inhalation so medication is conserved that would otherwise go to waste
- ✓ **Greater lung deposition**<sup>2</sup> - more aerosolised medication is delivered to the lungs compared to a conventional small volume jet nebuliser
- ✓ **Reduction in potentially harmful emissions**<sup>3</sup> - has substantially reduced environmental losses compared to non-breath actuated small volume nebulisers

<sup>†</sup> The AeroEclipse® XL BAN® Nebuliser is a single-patient use device, reusable for 6 months.



### Consistent medication delivery across a range of breathing patterns<sup>4</sup>

Inspiratory:Expiratory (I:E) ratio may vary from 1:1 to as much as 1:4 in the presence of obstructive lung disease




AeroEclipse® XL BAN® Nebuliser /  
Ombra® Table Top Compressor

3.0 mL fill of 2.5 mg salbutamol sulphate; tidal volume = 500 mL; n = 3 devices.  
The AeroEclipse® XL BAN® Nebuliser was operated in breath actuated mode.

### Higher drug delivery into the lungs<sup>5</sup>

Fine Droplet Fraction is the percentage of a dose that, because of its size, deposits in your lung



Respirable Dose = Total Mass Delivered x Fine Droplet Fraction  
5.0 mL fill of 300 mg tobramycin; tidal volume = 600 mL; inspiratory:expiratory ratio = 1:2; breaths per minute = 10; n = 5 devices/group. The AeroEclipse® XL BAN® Nebuliser was operated in breath actuated mode. BEN = breath enhanced nebuliser.



**AeroEclipse® XL**

BAN® Nebuliser

**OMBRA®**

Compressors

# Designed with patients in mind

## AeroEclipse<sup>®</sup> XL

BAN<sup>®</sup> Nebuliser

- ✓ Single-patient use, reusable for 6 months
- ✓ Disassembles into just 4 parts for easy cleaning and disinfection
- ✓ Dishwasher safe
- ✓ Disinfection by boiling,<sup>‡</sup> electronic steam disinfectant,<sup>‡</sup> microwave steam bag, 70% isopropyl alcohol,<sup>‡</sup> bleach, Milton,<sup>‡</sup> Dodie,<sup>‡</sup> Control III,<sup>‡</sup> Cidex,<sup>‡</sup> or vinegar

<sup>‡</sup> Meets US Cystic Fibrosis Foundation guidelines for cleaning and disinfection<sup>‡</sup>

Refer to the [instructions for use](#) for additional information.

OPEP = oscillating positive expiratory pressure



**Green feedback button** moves down as you inhale to encourage slow, deep breath

**Mouthpiece** can be removed and replaced with a mask

**Exhalation valve** directs exhaled breath away from your face and eyes

**ComfortSeal<sup>®</sup>** Masks contour gently to the face providing a secure and comfortable fit. Available in small, medium and large sizes. 6 months, reusable

**Aerobika<sup>®</sup>** OPEP device can be attached for combined treatment



## OMBRA<sup>®</sup> Table Top Compressor System

- ✓ Silicone cover keeps the power switch free of dust and dirt
- ✓ Contoured handle with nebuliser cup holder for added convenience
- ✓ Carrying case keeps treatment accessories organised
- ✓ Includes compressor, two AeroEclipse<sup>®</sup> XL BAN<sup>®</sup> Nebulisers with mouthpiece and tubing, five replacement air filters, carrying case and instructions



### TECHNICAL SPECIFICATIONS

Electrical Requirement	230 Volt AC
Weight	1.59 kg (3.5 lb)
Dimensions (L, W, H)	17.8 cm x 15.5 cm x 10 cm (7 in x 6.1 in x 3.9 in)
Sound Level	60 dB(A)
Minimum Pressure	103 kPa (15 psi)
Part Number	10551593006

1 Suggett J, et al. Respiratory Drug Delivery 2014;3:573-576. 2 Corcoran T, et al. Respiratory Care 2019;64(10):3235398. (This study used the AeroEclipse<sup>®</sup> XL BAN<sup>®</sup> Nebuliser.) 3 Nagel M, et al. Respiratory Drug Delivery 2021;11:287-292. (This study used the AeroEclipse<sup>®</sup> XL BAN<sup>®</sup> Nebuliser.) 4 Suggett J, et al. American Journal of Respiratory and Critical Care Medicine 2016;193:A5843. 5 Suggett J, et al. American Journal of Respiratory and Critical Care Medicine 2014;189:A2847. 6 Salzman L, et al. Cystic Fibrosis Foundation Guideline: Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update. Infection Control and Hospital Epidemiology. 2014;35(5):S1-S67. MD-576A-0425 \*TM trade marks and registered trade marks of Trudell Medical International (TMI). † trade marks and registered trademarks of their respective companies. © TMI 2025. All rights reserved.



TRUDELL MEDICAL  
UK LIMITED



Designed and  
Developed in Canada

Manufactured in Canada with  
Canadian and imported parts.

LEARN  
MORE



453-UK-EN